Vonicog alfa: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 00:43, 18 March 2025
Vonicog alfa is a recombinant form of human coagulation factor XIII A-subunit. It is produced by recombinant DNA technology in a human cell line. Vonicog alfa is used for the routine prophylactic treatment of congenital factor XIII A-subunit deficiency.
Etymology[edit]
The name "Vonicog alfa" is derived from the words "von Willebrand factor" and "coagulation factor". The suffix "alfa" indicates that it is a recombinant form of the protein.
Medical Uses[edit]
Vonicog alfa is used for the routine prophylactic treatment of congenital factor XIII A-subunit deficiency. This is a rare and potentially life-threatening disorder that is characterized by abnormal blood clotting that can result in abnormal bleeding. Vonicog alfa works by replacing the missing coagulation factor XIII A-subunit in patients with this disorder.
Pharmacology[edit]
Vonicog alfa is a recombinant form of human coagulation factor XIII A-subunit. It is produced by recombinant DNA technology in a human cell line. The protein is secreted into the cell culture medium, purified, and formulated into a sterile solution for intravenous injection.
Side Effects[edit]
The most common side effects of vonicog alfa include headache, pain in the extremities, and injection site reactions. Less common side effects include allergic reactions, which can be serious and require immediate medical attention.
